Technical Analysis for ICPT - Intercept Pharmaceuticals, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
A | 20.75 | -4.42% | -0.96 |
Earnings due: Feb 28
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New 52 Week High | Strength | 0.00% | |
Upper Bollinger Band Walk | Strength | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Overbought Stochastic | Strength | 0.00% | |
Upper Bollinger Band Touch | Strength | 0.00% | |
New 52 Week Closing High | Bullish | -4.42% | |
Pocket Pivot | Bullish Swing Setup | -4.42% | |
New 52 Week High | Strength | -4.42% | |
Upper Bollinger Band Walk | Strength | -4.42% | |
Wide Bands | Range Expansion | -4.42% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
Down 3% | about 11 hours ago |
Down 2 % | about 13 hours ago |
60 Minute Opening Range Breakdown | about 13 hours ago |
Rose Above Previous Day's High | about 14 hours ago |
New 52 Week High | about 14 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 02/28/2023
Intercept Pharmaceuticals, Inc. Description
Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry. It primarily develops obeticholic acid, a bile acid analog and farnesoid X receptor (FXR) agonist that is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trials to treat portal hypertension; in Phase IIb clinical trials for the nonalcoholic steatohepatitis treatment; and in Phase IIa trials for the treatment of bile acid diarrhea. The company is also developing INT-767, an orally administered FXR and TGR5 agonist, which is in preclinical studies to treat fibrosis; and INT-777, an orally administered TGR5 agonist that has completed preclinical studies for the treatment of type 2 diabetes. It has strategic collaborations and research agreements with Dainippon Sumitomo Pharma Co. Ltd. and TES Pharma Srl. The company was founded in 2002 and is headquartered in New York, New York. Intercept Pharmaceuticals, Inc. is a subsidiary of Genextra S.p.A.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Acid Alcohol Diabetes Hypertension Gastroenterology Steatohepatitis Diarrhea Liver Disease Hepatology Fibrosis Digestive Diseases Bile Acid Chronic Liver Disease Chronic Liver Diseases Primary Biliary Cholangitis Cirrhosis Farnesoid X Receptor Fxr Obeticholic Acid
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 21.86 |
52 Week Low | 10.81 |
Average Volume | 788,553 |
200-Day Moving Average | 15.49 |
50-Day Moving Average | 15.36 |
20-Day Moving Average | 17.74 |
10-Day Moving Average | 19.30 |
Average True Range | 1.01 |
RSI | 70.41 |
ADX | 42.32 |
+DI | 39.93 |
-DI | 7.52 |
Chandelier Exit (Long, 3 ATRs) | 18.83 |
Chandelier Exit (Short, 3 ATRs) | 17.09 |
Upper Bollinger Bands | 21.52 |
Lower Bollinger Band | 13.96 |
Percent B (%b) | 0.9 |
BandWidth | 42.62 |
MACD Line | 1.60 |
MACD Signal Line | 1.27 |
MACD Histogram | 0.3304 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 22.42 | ||||
Resistance 3 (R3) | 22.60 | 22.23 | 22.14 | ||
Resistance 2 (R2) | 22.23 | 21.81 | 22.14 | 22.04 | |
Resistance 1 (R1) | 21.49 | 21.54 | 21.31 | 21.31 | 21.95 |
Pivot Point | 21.12 | 21.12 | 21.03 | 21.03 | 21.12 |
Support 1 (S1) | 20.38 | 20.70 | 20.20 | 20.20 | 19.55 |
Support 2 (S2) | 20.01 | 20.43 | 19.92 | 19.46 | |
Support 3 (S3) | 19.27 | 20.01 | 19.36 | ||
Support 4 (S4) | 19.09 |